[go: up one dir, main page]

MX2019011844A - Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato. - Google Patents

Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato.

Info

Publication number
MX2019011844A
MX2019011844A MX2019011844A MX2019011844A MX2019011844A MX 2019011844 A MX2019011844 A MX 2019011844A MX 2019011844 A MX2019011844 A MX 2019011844A MX 2019011844 A MX2019011844 A MX 2019011844A MX 2019011844 A MX2019011844 A MX 2019011844A
Authority
MX
Mexico
Prior art keywords
preparation
formula
compounds
acid derivatives
bile acid
Prior art date
Application number
MX2019011844A
Other languages
English (en)
Other versions
MX388300B (es
Inventor
Yat Sun Or
Yong He
Guoqiang Wang
Xuechao Xing
Brett Granger
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of MX2019011844A publication Critical patent/MX2019011844A/es
Publication of MX388300B publication Critical patent/MX388300B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con procesos para la preparación de compuestos de la Fórmula (I) y compuestos de la Fórmula (II): o un solvato o sal farmacéuticamente aceptable del mismo. Estos compuestos y composiciones farmacéuticas son útiles como moduladores de FXR o TGR5. Específicamente, la presente invención se refiere a derivados de ácidos biliares y métodos para su preparación y uso. La presente invención se refiere a un proceso para la preparación de los compuestos de la Fórmula (III), Fórmula (IV), Fórmula (V) y Fórmula (VI), La presente invención también se refiere a un proceso para la preparación de los compuestos (VII), (VIII) y (IX),.
MX2019011844A 2017-04-07 2018-04-09 Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato MX388300B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762483044P 2017-04-07 2017-04-07
PCT/US2018/026696 WO2018187804A1 (en) 2017-04-07 2018-04-09 Process for preparation of sulfonyl carbamate bile acid derivatives

Publications (2)

Publication Number Publication Date
MX2019011844A true MX2019011844A (es) 2021-11-30
MX388300B MX388300B (es) 2025-03-19

Family

ID=63710729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011844A MX388300B (es) 2017-04-07 2018-04-09 Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato

Country Status (12)

Country Link
US (2) US10676500B2 (es)
EP (1) EP3606533B1 (es)
JP (1) JP7136802B2 (es)
KR (1) KR102624997B1 (es)
CN (1) CN110612105B (es)
AU (1) AU2018249950B2 (es)
BR (1) BR112019020780A2 (es)
CA (1) CA3058754A1 (es)
ES (1) ES2971092T3 (es)
IL (1) IL269859B2 (es)
MX (1) MX388300B (es)
WO (1) WO2018187804A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170094184A (ko) 2014-11-06 2017-08-17 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
KR20170099909A (ko) 2014-11-26 2017-09-01 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
ES2886766T3 (es) 2015-03-31 2021-12-20 Enanta Pharm Inc Derivados del ácido biliar como agonistas de FXR/TGR5 y métodos de uso de estos
CN110121347A (zh) * 2016-11-29 2019-08-13 英安塔制药有限公司 制备磺酰脲胆汁酸衍生物的方法
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
EP3606533B1 (en) 2017-04-07 2023-11-15 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
CN112341512A (zh) * 2020-04-13 2021-02-09 苏州恩泰新材料科技有限公司 由海豹胆酸制备鹅去氧胆酸的方法
CN112300237A (zh) * 2020-04-13 2021-02-02 苏州恩泰新材料科技有限公司 海豹胆酸的制备方法及其应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1592791A (en) 1977-01-07 1981-07-08 Radiochemical Centre Ltd Selenium- or tellurium-containing bile acids and derivatives thereof
EP0243449A1 (en) 1985-10-18 1987-11-04 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
IT1255449B (it) 1992-06-30 1995-10-31 Fabio Berlati Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.
IT1255485B (it) 1992-08-04 1995-11-06 Erregierre Ind Chim Processo per preparare gli acidi biliari coniugati con la glicina e relative composizioni terapeutiche per il trattamento dell'insufficienza epatica
TW289020B (es) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
TW289757B (es) 1993-05-08 1996-11-01 Hoechst Ag
US5541348A (en) 1994-03-10 1996-07-30 National Research Council Of Canada Bile acids for biological and chemical applications and processes for the production thereof
US5646316A (en) 1994-04-08 1997-07-08 Osteoarthritis Sciences, Inc. Bile acid inhibitors of metalloproteinase enzymes
JPH1160594A (ja) 1997-08-25 1999-03-02 Sankyo Co Ltd 胆汁酸誘導体
JP3865890B2 (ja) 1997-09-30 2007-01-10 富士フイルムホールディングス株式会社 ポジ型感光性組成物
US6639078B1 (en) 1998-12-23 2003-10-28 Smithkline Beecham Corporation Assays for ligands for nuclear receptors
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
DK1104760T3 (da) 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
DK1305296T3 (da) 2000-07-26 2009-12-14 Us Gov Health & Human Serv 5-substituerede pyrimidinderivater af konformationsfastlagte nucleosidanaloge
US20020098999A1 (en) 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
WO2002028881A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US7138390B2 (en) 2001-03-12 2006-11-21 Intercept Pharmaceuticals Steroids as agonists for FXR
AU2003228485A1 (en) 2002-04-12 2003-10-27 The University Of Chicago Farnesoid x-activated receptor agonists
ITMI20021080A1 (it) 2002-05-21 2003-11-21 Marcello Izzo Associazioni farmaceutiche per uso topico a base di chelati del ferroinibitori delle metalloproteasi e fattore xiii per il trattamento dell
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
SI1734970T1 (sl) 2004-03-12 2015-04-30 Intercept Pharmaceuticals, Inc. Zdravljenje fibroze z uporabo FXR ligandov
US20090192077A1 (en) 2005-04-15 2009-07-30 Shizuko Sei North-2'deoxy -methanocarbathymidines as antiviral agents for treatment of kaposi's sarcoma-associated herpes virus
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US20070190067A1 (en) 2006-02-01 2007-08-16 Savage Paul B Cationic Steroid Antimicrobial Compositions and Methods of Use
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
WO2007111994A2 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
WO2008002573A2 (en) 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
US20090258847A1 (en) 2006-07-17 2009-10-15 Erwin Paul Schreiner Cholanic Acid Amides
EP1947108A1 (en) 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
EP2112995B1 (en) 2007-01-19 2013-07-31 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as tgr5 modulators and methods of use thereof
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
WO2009032321A2 (en) 2007-09-06 2009-03-12 Genaera Corporation A method for treating diabetes
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
KR101239008B1 (ko) 2008-03-31 2013-03-04 한양대학교 산학협력단 바일산 유도체 및 그의 응용
CN105037476B (zh) 2008-07-30 2018-06-12 英特塞普特医药品公司 Tgr5调节剂及其使用方法
US8603737B2 (en) 2008-09-19 2013-12-10 Celgene Avilomics Research, Inc. Methods for identifying HCV protease inhibitors
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013020108A2 (en) 2011-08-04 2013-02-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pancreatitis
WO2013043554A1 (en) 2011-09-23 2013-03-28 Access Business Group International Llc Methods for creating recommended dietary regime
WO2013049595A1 (en) 2011-09-29 2013-04-04 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
WO2013166176A1 (en) 2012-05-01 2013-11-07 Catabasis Pharmaceuticals, Inc. Fatty acid conjugates of statin and fxr agonists; compositions and method of uses
SG11201408501UA (en) 2012-06-19 2015-01-29 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
WO2014036377A1 (en) 2012-08-31 2014-03-06 Metselex Methods of promoting cell viability
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140206657A1 (en) 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
PT2997035T (pt) 2013-05-14 2018-07-18 Intercept Pharmaceuticals Inc Derivados de 11-hidroxilo substituídos em 6 de ácidos biliares e seus conjugados de aminoácido como moduladores do recetor farnesoide x
AU2014296023B2 (en) 2013-08-01 2020-02-06 The Penn State Research Foundation Inhibitors of the farnesoid X receptor and uses in medicine
US20150112089A1 (en) 2013-10-22 2015-04-23 Metselex, Inc. Deuterated bile acids
CN106661079B (zh) 2014-05-29 2019-03-01 巴尔制药有限公司 用于治疗和/或预防fxr和tgr5/gpbar1介导的疾病的胆烷衍生物
KR20170094184A (ko) 2014-11-06 2017-08-17 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
CN111944006B (zh) * 2014-11-17 2021-12-17 正大天晴药业集团股份有限公司 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途
KR20170099909A (ko) 2014-11-26 2017-09-01 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
US20160176917A1 (en) 2014-11-26 2016-06-23 Enanta Pharmaceuticals, Inc. Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) * 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2016130809A1 (en) 2015-02-11 2016-08-18 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
ES2886766T3 (es) * 2015-03-31 2021-12-20 Enanta Pharm Inc Derivados del ácido biliar como agonistas de FXR/TGR5 y métodos de uso de estos
CN111116699B (zh) 2015-04-28 2023-02-28 江苏豪森药业集团有限公司 胆酸衍生物及其制备方法和医药用途
CN106083978A (zh) 2015-04-28 2016-11-09 上海迪诺医药科技有限公司 磺酰基氨基羰基衍生物、其药物组合物及应用
CN107531743B (zh) 2015-04-29 2020-05-05 正大天晴药业集团股份有限公司 鹅去氧胆酸衍生物
CN107771180B (zh) 2015-06-19 2021-03-23 英特塞普特医药品公司 Tgr5调节剂及其使用方法
AU2016306297A1 (en) 2015-08-07 2018-02-22 Intercept Pharmaceuticals, Inc. Methods for preparation of bile acids and derivatives thereof
CN105175473B (zh) 2015-08-19 2018-12-21 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用
KR20180052756A (ko) 2015-09-24 2018-05-18 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체
MA45761A (fr) 2015-10-07 2021-04-21 Intercept Pharmaceuticals Inc Modulateurs du récepteur farnésoïde x
MY196292A (en) 2016-01-28 2023-03-24 Chia Tai Tianqing Pharmaceutical Group Co Ltd Steroid Derivative Fxr Agonist
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
CA3016875C (en) 2016-03-11 2023-08-22 Intercept Pharmaceuticals, Inc. 3-desoxy derivative and pharmaceutical compositions thereof
CN110121347A (zh) 2016-11-29 2019-08-13 英安塔制药有限公司 制备磺酰脲胆汁酸衍生物的方法
WO2018152171A1 (en) * 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
EP3606533B1 (en) 2017-04-07 2023-11-15 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives

Also Published As

Publication number Publication date
RU2019135044A (ru) 2021-05-07
MX388300B (es) 2025-03-19
BR112019020780A2 (pt) 2020-04-28
KR102624997B1 (ko) 2024-01-12
RU2019135044A3 (es) 2021-12-29
US20180291058A1 (en) 2018-10-11
IL269859A (en) 2019-11-28
EP3606533A4 (en) 2021-05-26
US10961272B2 (en) 2021-03-30
JP2020512994A (ja) 2020-04-30
CN110612105A (zh) 2019-12-24
ES2971092T3 (es) 2024-06-03
CN110612105B (zh) 2023-05-02
AU2018249950B2 (en) 2023-09-21
CA3058754A1 (en) 2018-10-11
WO2018187804A1 (en) 2018-10-11
EP3606533B1 (en) 2023-11-15
AU2018249950A1 (en) 2019-11-07
EP3606533A1 (en) 2020-02-12
US20200317717A1 (en) 2020-10-08
JP7136802B2 (ja) 2022-09-13
KR20200010215A (ko) 2020-01-30
IL269859B2 (en) 2023-06-01
US10676500B2 (en) 2020-06-09

Similar Documents

Publication Publication Date Title
MX2019011844A (es) Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato.
MX378555B (es) Proceso para la preparacion de derivados del acido biliar de las sulfonilureas
CY1124404T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων
EP4365179A3 (en) Novel rapamycin derivatives
SA520411222B1 (ar) مركبات بوصفها معدلات لعامل باديء حقيقي النواة 2ب وتركيبات وطرق
TN2018000106A1 (en) Farnesoid x receptor modulators
MX2018001491A (es) Metodos para la preparacion de acidos biliares y derivados de los mismos.
HK1244708A1 (zh) 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法
PH12016501440A1 (en) Novel heterocyclic compounds
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EP4252848A3 (en) Oxysterols and methods of use thereof
HK1243930A1 (zh) 作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
MX2015005286A (es) Procedimiento para la preparación de derivados del ácido biliar.
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
AU2018253590A1 (en) Imidazopyridazine compounds
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
MA43066A (fr) Procédés de préparation d'acides biliaires et de leurs dérivés
WO2017177004A8 (en) Tertiary amides and method of use
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
PH12014501711A1 (en) Benzyl sulfonamide derivatives useful as mogat-2 inhibitors
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).